Anna Minchom

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Martin Schüler, Gopa Iyer et al. · The Lancet Oncology · 2023 · 175 citations · Full text

Fgfr Alterations, Medicine, Pathology +7

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Byoung Chul Cho, Dong‐Wan Kim, Alexander I. Spira et al. · Nature Medicine · 2023 · 96 citations · Full text

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim et al. · Journal of Clinical Oncology · 2024 · 94 citations · Full text

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations

Lyudmila Bazhenova, Anna Minchom, Santiago Viteri et al. · Lung Cancer · 2021 · 75 citations

BRIM-1, -2 and -3 Trials: Improved Survival with Vemurafenib in Metastatic Melanoma Patients with a BRAF ^V600E Mutation

Kate Young, Anna Minchom, James Larkin · Future Oncology · 2012 · 68 citations